46-3109-41

antibody from Invitrogen Antibodies

Targeting: HAVCR2 CD366, FLJ14428, Tim-3, TIM3, TIMD3

Flow cytometry (Supportive data in Antibodypedia)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

46-3109-41

Provider

Invitrogen Antibodies

Product name

CD366 (TIM3) Monoclonal Antibody (F38-2E2), PerCP-eFluor™ 710, eBioscience™

Antibody type

Monoclonal

Antigen

Other

Description

Description: This F38-2E2 monoclonal antibody reacts with human CD366, also known as T cell immunoglobulin and mucin domain-containing protein 3 (TIM3) or HAVCR2. This cell surface receptor is expressed on activated CD4+ T cell subsets (e.g. Th1, Th17, and Treg), CD8+ T cells, monocytes, dendritic cells, and mast cells. Due to alternative splicing, CD366 exists as membrane-bound and soluble forms. Galectin-9 has been identified as the ligand for CD366. In humans, this receptor negatively regulates CD4+ T cells, influencing the secretion of some Th1- and Th17-related cytokines. CD366 has also been implicated in tolerance, autoimmune disease (e.g. multiple sclerosis), and HIV infection.

Antibody clone number

F38-2E2

Concentration

5 µL/Test

References

Submitted references

TIGIT(+) TIM-3(+) NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma.

Yu L, Liu X, Wang X, Yan F, Wang P, Jiang Y, Du J, Yang Z
Oncoimmunology 2021;10(1):1942673

---

SLC1A1 mediated glutamine addiction and contributed to natural killer T-cell lymphoma progression with immunotherapeutic potential.

Xiong J, Wang N, Zhong HJ, Cui BW, Cheng S, Sun R, Chen JY, Xu PP, Cai G, Wang L, Sun XJ, Huang JY, Zhao WL
EBioMedicine 2021 Oct;72:103614

---

Single residue in CD28-costimulated CAR-T cells limits long-term persistence and antitumor durability.

Guedan S, Madar A, Casado-Medrano V, Shaw C, Wing A, Liu F, Young RM, June CH, Posey AD Jr
The Journal of clinical investigation 2020 Jun 1;130(6):3087-3097

---

Dynamics of NK, CD8 and Tfh cell mediated the production of cytokines and antiviral antibodies in Chinese patients with moderate COVID-19.

Yan L, Cai B, Li Y, Wang MJ, An YF, Deng R, Li DD, Wang LC, Xu H, Gao XD, Wang LL
Journal of cellular and molecular medicine 2020 Dec;24(24):14270-14279

---

TIGIT expressing CD4+T cells represent a tumor-supportive T cell subset in chronic lymphocytic leukemia.

Catakovic K, Gassner FJ, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, Steiner M, Gutjahr JC, Pleyer L, Egle A, Hartmann TN, Greil R, Geisberger R
Oncoimmunology 2017;7(1):e1371399

---

TIM-3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines.

Hastings WD, Anderson DE, Kassam N, Koguchi K, Greenfield EA, Kent SC, Zheng XX, Strom TB, Hafler DA, Kuchroo VK
European journal of immunology 2009 Sep;39(9):2492-501

Flow cytometry

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Human peripheral blood cells were unstimulated (left) or stimulated with Anti-Human CD3 (Product # 16-0037-81) and Anti-Human CD28 (Product # 16-0289-81) for 3 days (right). Cells were then stained with Anti-Human CD4 FITC (Product # 11-0049-42) and Anti-Human CD366 (TIM3) PerCP-eFluor® 710. Total viable cells were used for analysis.

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure2. The co-expression of TIGIT and TIM-3 is elevated on NK cells of progression patients with HBV-HCC. a-b Percentages of TIGIT + TIM-3 + NK cells on total NK cells and NK cell subsets(CD56 bright NK cells,CD56 dim NK cells, and CD56 - NK cells) from HBV-HCC, HDs, CHB and HBV-LC patients by flow cytometry analysis. c Correlation analysis of TIGIT and TIM-3 on NK cells from patients with HBV-HCC. d-e Flow-cytometry analyses (d) of TIGIT and TIM-3 were performed on PBMCs collected from HBV-HCC patients. Representative plots (e) display the expression of TIGIT + NK cells, TIM-3 + NK cells and total TIGIT + TIM-3 + NK cells from patients with progression (n = 61) and no progression (n = 72). P values were calculated by using the Kruskal-Wallis nonparametric H test (a-c). P values were obtained by the unpaired t test (d-e). * P < .05, ** P < .01, *** P < .001, **** P < .0001

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Fig. 5 Asparaginase treatment increased NKTCL cell sensitivity to anti-PD-1 antibody. (a) SLC1A1 expression on NK-92 cells transfected with SLC1A1 vector or control vector (upper panel) and SNK-6 cells transfected with SLC1A1 shRNA or scramble (lower panel). (b) Ki-67 and TIM-3 positivity of CD3+/CD8+ T cells in PBMC co-cultured with NK-92 cells (upper panel) or SNK-6 cells (lower panel) transfected with indicated vectors or shRNAs in medium with or without extra glutamine (2mM). (c) PD-L1 mRNA expression in NK-92 cells transfected with SLC1A1 vector or control vector (upper panel) and SNK-6 cells transfected with SLC1A1 shRNA or scramble (lower panel) upon asparaginase (10 IU/mL) treatment. The control vector or scramble values were normalized to 1, respectively. (d and e) Median fluorescence intensity of PD-L1 (d) on NK-92 cells (upper panel) or SNK-6 cells (lower panel), as well as Ki-67 and TIM-3 positivity of CD3+/CD8+ T cells in PBMC co-cultured with NK-92 cells (upper panel) or SNK-6 cells (lower panel) upon indicated treatment. (f) Gene expression correlation of tumor SLC1A1 with PD-L1 in NKTCL patients (n=128). (g) Tumor EAAT3 expression according to the TSIM, HEA, and MB subtypes in NKTCL patients (n=100). (h) PD-L1 mRNA expression of NK-92 cells transfected with TP53 R248Q, TP53 R273H, EP300 vector, or MGA shRNA upon indicated treatment. (i) Ki-67 positivity of CD3+/CD8+ T cells in PBMC co-cultured with NK-92 cells transfected with TP53 R248Q, TP53 R273H, EP300 vec